Insights

white paper

In the fall of 2021, the Delta variant of SARS-CoV-2 was the dominant strain in the US, being both more contagious than previous variants and more likely to lead to “long COVID” than subsequent Omicron variants. Here we describe the discovery and...

white paper

A large portion of innovative companies are in discovery, preclinical or early clinical stages with therapeutics aimed at oncology and infectious diseases. There is promising growth in overall biologics therapies, driven by increased funding and grow...

white paper

With experience in both chemistry and biologics, Curia is uniquely positioned to provide mRNA drug development solutions spanning discovery and engineering, mRNA drug substance formulation, and fill-finish and manufacturing of lipids and nucleosides.

white paper

The number of FDA-approved monoclonal antibodies (mAbs) continues to grow, while those in late-stage development rose more than 30% between 2021 and 2022.

white paper

Hybridoma technology is a popular method for antibody discovery, but the conventional approach of using a single inbred mouse strain for immunization fails to generate the diversity and antibody titers needed to maximize the discovery of high-quality...

white paper

The combination of the PentaMice® platform and single B cell screening with the Berkeley Lights Beacon® Optofluidic system increases speed to market for monoclonal antibody therapeutics.

white paper

The clinical value of biologics for the treatment of many disease indications has been accompanied by phenomenal sales. By 2026, the global market for biologics is projected to increase to $537 billion. However, getting a promising drug candidate fro...